Top Drugs To Watch in HIV (2025): There is a lot
Post# of 155550
(Total Views: 654)
Posted On: 06/15/2025 12:49:55 AM
Top Drugs To Watch in HIV (2025):
There is a lot of opportunity for emerging therapies for the multi-drug resistant (MDR) HIV-1 as only Rukobia and Trogarzo are approved in the market. Lenacapavir and Vyrologix (leronlimab) are the two emerging therapies expected to dominate the MDR HIV-1 market by 2030.
https://www.delveinsight.com/blog/emerging-therapies-for-hiv
____
Our Hiv-MDR abstract from the website:
https://journals.lww.com/jaids/abstract/2025/..._1.12.aspx
Keep in mind, Cytodyn removed our MDR-BLA because sections were taken from the HIV-BLA.
After that hold was lifted last year, always asked --- why not re-file the Hiv-MDR ?
Pool criss-cross data from MDR, mTNBC, CRC, Prostate & Glioblastoma if there just happens to be a brain mets in Ladies of Leronlimab.
File a BTD for each with the $2m expected from Amarex next month.
Start the fully funded Alzheimers.
Get 3rd party to start the PF trial.
Hiv Latch @ amfAR ramp up.
Announce a partner --- cash infusion...NASDAQ intent.
There is a lot of opportunity for emerging therapies for the multi-drug resistant (MDR) HIV-1 as only Rukobia and Trogarzo are approved in the market. Lenacapavir and Vyrologix (leronlimab) are the two emerging therapies expected to dominate the MDR HIV-1 market by 2030.
https://www.delveinsight.com/blog/emerging-therapies-for-hiv
____
Our Hiv-MDR abstract from the website:
https://journals.lww.com/jaids/abstract/2025/..._1.12.aspx
Keep in mind, Cytodyn removed our MDR-BLA because sections were taken from the HIV-BLA.
After that hold was lifted last year, always asked --- why not re-file the Hiv-MDR ?
Pool criss-cross data from MDR, mTNBC, CRC, Prostate & Glioblastoma if there just happens to be a brain mets in Ladies of Leronlimab.
File a BTD for each with the $2m expected from Amarex next month.
Start the fully funded Alzheimers.
Get 3rd party to start the PF trial.
Hiv Latch @ amfAR ramp up.
Announce a partner --- cash infusion...NASDAQ intent.
(4)
(0)